CRISPR Therapeutics AG (CRSP)
- Previous Close
54.06 - Open
54.26 - Bid 53.57 x 300
- Ask 53.78 x 300
- Day's Range
53.38 - 54.74 - 52 Week Range
37.55 - 91.10 - Volume
1,112,934 - Avg. Volume
1,313,234 - Market Cap (intraday)
4.563B - Beta (5Y Monthly) 1.79
- PE Ratio (TTM)
-- - EPS (TTM)
-2.70 - Earnings Date May 8, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
84.29
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
www.crisprtx.comRecent News: CRSP
Performance Overview: CRSP
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRSP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRSP
Valuation Measures
Market Cap
4.56B
Enterprise Value
2.69B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.92
Price/Book (mrq)
2.19
Enterprise Value/Revenue
9.96
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-79.91%
Return on Assets (ttm)
-7.97%
Return on Equity (ttm)
-11.02%
Revenue (ttm)
271.71M
Net Income Avi to Common (ttm)
-217.14M
Diluted EPS (ttm)
-2.70
Balance Sheet and Cash Flow
Total Cash (mrq)
2.11B
Total Debt/Equity (mrq)
11.27%
Levered Free Cash Flow (ttm)
-111.89M
Research Analysis: CRSP
Company Insights: CRSP
CRSP does not have Company Insights
Research Reports: CRSP
Crispr Earnings: Commercial Launch of Casgevy Is Underway; Positive Outlook and Shares Undervalued
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice TargetPositive Outlook for Crispr Therapeutics Thanks to Blockbuster Potential of Casgevy
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice TargetPositive Outlook for Crispr Therapeutics Thanks to Blockbuster Potential of Casgevy
Crispr Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice TargetCrispr Earnings: Blockbuster Potential for Casgevy; Shares Undervalued for Long-Term Investors
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR’s most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
RatingPrice Target